

## NPY Levels In Type 1 Diabetic Men of Different Duration.

Vittorio Coiro<sup>1</sup>, Riccardo Volpi<sup>1</sup>, Simona Cataldo<sup>2</sup>, Maria Grazia Magotti<sup>2</sup>, Luigi Capretti<sup>3</sup>, Anna Araldi<sup>1</sup>, Claudio Giumelli<sup>1</sup>, Teore Ferri<sup>4</sup>, Roberta Minelli<sup>1</sup>, Lavinia Volpi<sup>1</sup>, Paolo Chiodera<sup>1,2</sup>.

<sup>1</sup>Department of Internal Medicine and Biomedical Sciences, University of Parma

<sup>2</sup>Endocrine Service, Hospital of Parma

<sup>3</sup>Endocrine Unit, Hospital of Codogno

<sup>4</sup>Department of Otolaryngology, University of Parma

Short Title: NPY levels in diabetes mellitus

Word count: 1543.

Key Words: NPY, C-peptide, diabetes mellitus

Correspondence:

Vittorio Coiro, MD

Department of Internal Medicine and Biomedical Sciences, University of Parma

Via A. Gramsci 14

I-43126 Parma, Italy

Phone & Fax: 0035 0521 033296

e-mail: [vittorio.coiro@unipr.it](mailto:vittorio.coiro@unipr.it)

## Abstract

**Background:** The aim of the present study was to evaluate whether the different duration of type 1 diabetes mellitus influences basal NPY secretion.

**Design:** The NPY concentrations were measured in sixty-eight men with insulin-dependent diabetes mellitus (IDDM) (duration: group 1 (n.21) <5 years (range 2-4 years); group 2 (n.24) >5 years and <10 years (range: 6-9 years); group 3 (n.29) >10 years (range: 11-14 years)) and in age matched normal control subjects (n. 30).

**Results:** The NPY levels were significantly lower in group 3 than in group 2 and 1 and in the control group, in group 2 than in group 1 and in the control group and in group 1 than control group.

**Conclusion:** These results support the view that the duration of diabetes may have a modulatory role in the decreased basal NPY secretion observed in diabetics.

## Introduction

The metabolic disturbance of diabetes mellitus (DM) might cause adaptive change in the hypothalamic regulation of metabolic control. Such changes may involve regulatory peptides, which are known to affect food intake and glucoregulation<sup>1-3</sup>.

Disturbance of hypothalamic regulatory peptides could be associated with the impairment of hormonal activity in diabetes<sup>4,5</sup>. The identification of local regulatory peptides activity in diabetes may therefore help to clarify hypothalamic control mechanisms. NPY is one of the most widely spread neuropeptides in the rat brain. Large amount of NPY are present in several hypothalamic sites and immunopositive NPY fibers emanating from NPY producing perikarya in the hypothalamic arcuate nucleus and brain stem innervate several hypothalamic regions<sup>6,7</sup>. In addition, NPY plays an important role in the neuroendocrine regulation of eating behaviour<sup>1-3, 8-13</sup>.

Disturbances in NPY function has been observed in diabetes mellitus<sup>14,15</sup>. Altered hypothalamic NPY levels may mediate hyperphagia and polydipsia in diabetic rats<sup>16,17</sup> and thus disorders of NPY activity might exert an important influence on metabolic control in diabetes.

Previous studies indicated that different duration of insulin dependent diabetes mellitus (IDDM) play a role in the control of LH and AVP secretion. In fact diminution in LH and AVP secretory patterns appeared to be more evident in patients with time after the onset of IDDM<sup>18-20</sup>. In light of the difference in LH, AVP secretion, we wondered whether a similar difference also concerns NPY secretions. For this purpose, NPY circulating concentrations were measured in diabetic men affected by IDDM of different duration. The results obtained in these groups were compared with those observed in control age-matched normal men.

#### Subjects and methods

Fifty-eight insulin-dependent diabetic men, 23 to 46 years, participated in this study. The duration of diabetes ranged from 2 to 14 years. Patients were divided into three group of subjects according to the duration of their disease (group 1 (n. 21): <5 years, range 2-4 years; group 2 (n. 24): >5 years and <10 years, range 6-9 years; group 3 (n. 23): >10 years, range 11-14 years). The mean age  $\pm$  SE was 29.3 $\pm$ 1.8 years in subjects of group 1, 31.2 $\pm$ 1.4 in subjects of group 2 and 32.6 $\pm$ 1.8 in subjects of group 3. Thirty normal men (27 to 37 years of age) with normal body weight and without signs of endocrine diseases or family history of diabetes mellitus participated in this study as controls. All subjects were informed of the purpose of the study which was performed according to the Helsinki II declaration. The Ethical Committee of the University of Parma, reviewed the protocol of the study. None of the diabetic and control subjects were affected by major affective disorders as determined by the Hamilton Depressive Rating Scale. None of the diabetic patients received any drug, except insulin because of diabetes mellitus, for at least 20 days before the experimental days. From the onset of their illness, the patients had been treated with insulin and at the time of this study they were hospitalized for adjustment of insulin therapy. Venous blood samples were drawn

at 08.00 after a 12 h overnight fast after optimization of insulin administration, which was similar in both groups (dose of short acting and intermediate duration monocomponent insulin given together twice daily  $31.2 \pm 2.0$  IU/24h (mean  $\pm$  SE) (group 1),  $30.4 \pm 1.9$  IU/24 h (group 2),  $32.0 \pm 1.9$  IU/24h group 3. Insulin therapy did not change because the subjects had achieved a good control of their metabolic status [average blood glucose:  $7.9 \pm 0.8$  nmol/l (mean  $\pm$  SE) (group 1),  $7.8 \pm 0.6$  (group 2),  $7.7 \pm 0.6$  group 3; percent of glycosilated haemoglobin (HbA1c):  $7.0 \pm 0.8$  (mean  $\pm$  SE) (group 1),  $7.3 \pm 0.7$  (group 2),  $7.4 \pm 0.6$  group 3]. No patient had clinical or laboratory evidence of ketosis or of associated endocrine or other intercurrent diseases. No signs of autonomic or somatic nerve dysfunction or vascular disease were present in any patients. In all of them creatinine clearance was in the normal range of values ( $96.4 \pm 4.3$  ml/min (mean  $\pm$  SE) (group 1),  $96.2 \pm 3.9$  (group 2)  $97.6 \pm 21.0$  group 3; microalbuminuria was absent in all subjects. The mean ( $\pm$  SE) blood pressure was  $96.5 \pm 1.1$  mmHg (group 1),  $98.1 \pm 1.4$  mmHg (group 2),  $97.8 \pm 1.3$  (group 3),  $97.1 \pm 1.4$  mmHg (controls). All patients underwent ophthalmologic examination to detect the presence of diabetic retinopathy.

Diagnostic criteria. After papillary dilatation patients underwent ophthalmoscopic examination performed by the same experienced ophthalmologist. The finding of at least three microaneurysms was considered a sign of retinopathy. Patients with retinopathy were excluded from the study. As control indices of the metabolic status of these patients, blood glucose levels were measured at 7.30 AM, 11.00 AM and 05.00 PM on the day preceding this experimental study. For each patient, a mean value of blood glucose was obtained by averaging these three determinations. On the experimental day, blood samples were taken for evaluation of glycaemia and HbA1c.

Blood glucose concentrations were measured with a glucose oxidase-peroxidase procedure, using an IL 918 autoanalyzer (Instrumentation Laboratory, Milan, Italy). HbA1c was measured with reagents obtained from Bio-Rad Laboratories (CA, USA). In our laboratory the normal range of values for HbA1c is 4.1-6.5%. Plasma NPY levels were measured by RIA utilizing commercial kits. The intra-assay and inter-assay coefficients of variation were: 3.6% and 11.0%, respectively.

The sensitivity of the method was 6 pmol/l. Results were analyzed statistically with non-parametric Mann-Whitney U test, and linear correlation coefficient of variation as appropriate. All data are reported as mean  $\pm$  SE.

## Results

Clinical and biochemical characteristics of diabetic patients and normal controls are shown in Table 1.

Plasma NPY levels were significantly lower in group 2 than in group 1 ( $P < 0.01$ ) and normal controls ( $P < 0.01$ ). In group 1 NPY concentrations were lower than in normal controls ( $P < 0.01$ ) (Fig. 1). When data obtained in patients of group 1, group 2 and group 3 were combined, significant negative correlations were found between duration of diabetes mellitus and NPY concentrations ( $r = -0.720$ ;  $P < 0.01$ ).

## Discussion

Our data suggest that changes in plasma NPY levels in diabetics are influenced by the duration of the diabetic condition. On the other hand, our patients were in similar metabolic status at the moment of the study; and thus the alteration in NPY concentrations cannot be attributed to the intercurrent factors such as decreased body weight, poor nutritional conditions or chronic organic disorders. More likely the abnormal NPY levels depended on the diabetic conditions per se. A limitation of the present study is the measurement of a single fasting hormone concentration. However, fasting NPY concentrations is a representative sample of baseline conditions, without the influences of pre-prandial or post-prandial factors because NPY concentrations may be influenced by food intake. In fact, the evaluation of fasting hormone level is usually a reference point to compare two or more populations under different conditions. Because of these reasons, we decided to evaluate NPY levels in fasting conditions.

The source of circulating NPY concentration remains unclear. NPY is mainly reported to be present in the hypothalamic sites including paraventricular and arcuate nucleus<sup>21</sup>. The blood brain barrier (BBB) inhibits the release of peptides into the circulation from various structures in the brain; however the arcuate nucleus is known to be a region where the BBB is absent<sup>22</sup>. Therefore, the secretion of NPY from this structure into the blood stream is possible.

NPY has been also found in the autonomic sympathetic nerve. A recent study reported a mouse model which over-expresses NPY exclusively in the noradrenergic neurons to evaluate its systemic actions when expressed outside of the hypothalamus and the BBB<sup>23</sup>. In fact, although they described an increase of NPY within sympathetic neurons, its blood concentrations were not altered in rats. Therefore it is unlikely that autonomic sympathetic neurons are a source of circulating NPY. The progressive decline of NPY levels with long-term IDDM might be explained by diabetes-related alteration of the NPY cell but also it is possible that an unstable glycemic control lasting for a long time produced neuroendocrine damages due to relative insulin deficiency; these alterations were not reversed by 3 days of continuous insulin infusion before the experiments. Previous reports showed decreased concentrations of plasma NPY in subjects with type 1 diabetes mellitus<sup>24</sup>. In contrast, it has been shown an elevation of NPY in type 2 diabetes mellitus patients<sup>25,26</sup>. In diabetics, this suggests that differences in the metabolic status of diabetics might affect the circulating concentrations of NPY. As to how relative insulin deficiency may produce NPY alterations<sup>14</sup> and the site of this action are still unknown.

A question arising from our data concerns the consequences of the decreased NPY secretion. Injection of NPY is known to stimulate appetite<sup>27,28</sup>. Therefore the change in ingestive behaviour in diabetes mellitus may be attributed to an altered release of NPY.

The activity of NPYergic neurons in the hypothalamic centers involved in these functions may be responsible for the multitude of effects on reproductive, feeding and sexual behaviour in diabetic subjects<sup>27,28</sup>. Our data suggest that NPYergic activity is strongly related with time after the onset of IDDM. Further studies are needed to substantiate these hypotheses.

## References

1. Leibowitz SF. Brain monoamines and peptides: role in the control of eating behavior. *Fed Proc.* 1986; **45**: 1396-403.
2. Frohman LA. CNS peptides and glucoregulation. *Annu Rev Physiol.* 1983 **45** 95-107.
3. Iguchi A, Matsunaga H, Nomura T, Gotoh M, Sakamoto N. Glucoregulatory effects of intrahypothalamic injections of bombesin and other peptides. *Endocrinology* 1984; **114**: 2242-2246.
4. Bluet-Pajot MT, Durand D, Kordon C. Influence of streptozotocin-induced diabetes on growth hormone secretion in the rat. *Neuroendocrinology* 1983; **36**: 307-309.
5. González C, Montoya E, Jolín T. Effect of streptozotocin diabetes on the hypothalamic-pituitary-thyroid axis in the rat. *Endocrinology* 1980; **107**: 2099-2103.
6. Gray TS, Morley JE. Neuropeptide Y: anatomical distribution and possible function in mammalian nervous system. *Life Sci.* 1986; **38**: 389-401.
7. Fetissov SO, Kopp J, Hökfelt T. Distribution of NPY receptors in the hypothalamus. *Neuropeptides* 2004; **38**: 175-188.
8. Mormède P, Castagné V, Rivet JM, Gaillard R, Corder R. Involvement of neuropeptide Y in neuroendocrine stress responses. Central and peripheral studies. *J Neural Transm Suppl.* 1990; **29**: 65-75.
9. Menéndez JA, McGregor IS, Healey PA, Atrens DM, Leibowitz SF. Metabolic effects of neuropeptide Y injections into the paraventricular nucleus of the hypothalamus. *Brain Res* 1990; **516**: 8-14.
10. Rettori V, Milenkovic L, Aguila MC, McCann SM. Physiologically significant effect of neuropeptide Y to suppress growth hormone release by stimulating somatostatin discharge. *Endocrinology* 1990; **126**: 2296-2301.

11. McDonald JK, Lumpkin MD, Samson WK, McCann SM. Neuropeptide Y affects secretion of luteinizing hormone and growth hormone in ovariectomized rats. *Proc Natl Acad Sci USA* 1985; **82**: 561-564.
12. Small CJ, Morgan DG, Meeran K, Heath MM, Gunn I, Edwards CM et al. Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release. *Proc Natl Acad Sci USA*. 1997; **94**: 11686-11691.
13. Sibbald JR, Wilson BK, Day TA. Neuropeptide Y potentiates excitation of supraoptic neurosecretory cells by noradrenaline. *Brain Res* 1989; **499**: 164-168.
14. Williams G, Steel JH, Cardoso H, Ghatei MA, Lee YC, Gill JS et al. Increased hypothalamic neuropeptide Y concentrations in diabetic rat. *Diabetes* 1988; **37**: 763-772.
15. Sahu A, Sninsky CA, Kalra PS, Kalra SP. Neuropeptide-Y concentration in microdissected hypothalamic regions and in vitro release from the medial basal hypothalamus-preoptic area of streptozotocin-diabetic rats with and without insulin substitution therapy. *Endocrinology* 1990; **126**: 192-198.
16. Morley JE, Levine AS, Gosnell BA, Kneip J, Grace M. Effect of neuropeptide Y on ingestive behaviors in the rat. *Am J Physiol* 1987; **252**: R599-R609.
17. Koopmans HS, Xavier Pi-Sunyer F. Large changes in food intake in diabetic rats fed high-fat and low-fat diets. *Brain Res Bull* 1986; **17**: 861-871.
18. Coiro V, Volpi R, Capretti L, Speroni G, Castelli A, Chiodera P. Luteinizing hormone response to gonadotropin-releasing hormone and naloxone in menstruating women with type 1 diabetes of different duration. *Fert Ster* 1991; **55**: 712-716.
19. Coiro V, Volpi R, Capretti L, Colla R, Caffarri G, Vescovi PP et al. Dopaminergic and cholinergic control of arginine-vasopressin secretion in type 1 diabetic men. *Eur J Clin Invest* 1995; **25**: 412-417.



20. Volpi R, Chiodera P, Gramellini D, Capretti L, Caffarri G, Speroni G et al. Influence of residual insulin secretion and duration of diabetes mellitus on the control of luteinizing hormone secretion in women. *Eur J Clin Invest* 1998; **28**: 819-825.
21. Bai FL, Yamano M, Shiotani Y, Emson PC, Smith AD, Powell JF et al. An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat. *Brain Res* 1985; **331**: 172-175.
22. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. *Endocr Rev* 1999; **20**: 68-100.
23. Ruohonen ST, Pesonen U, Moritz N, Kaipio K, Røyttä M, Koulu M et al. Transgenic mice overexpressing neuropeptide Y in noradrenergic neurons: a novel model of increased adiposity and impaired glucose tolerance. *Diabetes* 2008; **57**: 1517-1525.
24. Tallroth G, Ryding E, Ekman R, Agard CD. The response of regulatory peptides to moderate hypoglycaemia of short duration in type 1 (insulin-dependent)( diabetes mellitus and in normal man. *Diabetes Res* 1992; **20**: 73-85.
25. Illman A, Rasul S, Dimitrou A, Handisurya A, Gartner W, Baumgartner-Parzer S et al. Plasma neuropeptide Y differ in distinct diabetic conditions. *Neuropeptides* 2010; **44**: 485-489.
26. Sundkvist G, Bramnert M, Bergström B, Manhem P, Lilja B, Ahrén B. Plasma neuropeptide Y (NPY) and galanin before and during exercise in type 1 diabetic patients with autonomic dysfunction. *Diabetes Res Clin Pract* 1992; **15**: 219-226.
27. Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. *Endocrinology* 1984; **115**: 427-429.
28. Clark JT, Kalra PS, Kalra SP. Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats. *Endocrinology* 1985; **117**: 2435-2442.

Legend to the Fig. 1

Basal NPY levels (mean  $\pm$  SE) in normal controls and in Group 1 and in Group 2 of patients with diabetes mellitus.




Table 1 Clinical and biochemical data of the diabetic men (groups 2 and 3) and normal controls

	Age (years)	Weight (kg)	BMI	Duration of IDDM	Blood glucose (mmol/L <sup>-1</sup> )	HbA1c (%)
Group 1 (n= 21)	29.3±1.8	65.4±1.4	22.0±0.5	<5 (2-4 years)	7.9±0.8	7.0±0.8
Group 2 (n= 23)	31.2±1.4	64.8±1.7	22.6±0.6	>5 and <10 (6-9 years)	7.8±0.6	7.3±0.7
Control group (n= 30)	32.7±1.6	67.4±1.8	23.4±0.4		4.7±0.2	5.6±0.3

BMI = Body mass index